title: Evaluation of biological potential of smooth muscle tumours.
abstract: Smooth muscle tumours (SMTs) have been traditionally divided into benign leiomyomas (LM) and malignant leiomyosarcomas (LMS) based on cytological atypia, mitotic activity and other criteria. In most instances, this dichotomous approach works, but in some instances the biological potential cannot be determined with certainty. This is often because some, but not all criteria for malignancy have been met or because the tumours are occurring in unusual settings for which there are sparse substantive data. Tumours falling into the latter categories are often designated as 'smooth muscle tumours of uncertain malignant potential'. For most non-hormonally influenced SMTs, the presence of significant atypia plus mitotic activity equates with a diagnosis of LMS. However, not all tumours classified as LMSs have a similar prognosis, as a number of other factors, including tumour size, depth, grade and resectability, affect outcome. For example, cutaneous SMTs, regardless of mitotic activity and atypia, have potential largely limited to local recurrence, whereas subcutaneous and deep LMSs have a definite metastatic potential. Angioleiomyoma is the most common SMT of peripheral soft tissues, but deep peripheral LMs are distinctly rare and should be approached with caution. Hormonally influenced oestrogen- and progesterone receptor-positive uterine and extrauterine SMTs in women have unique criteria, including the allowance of higher mitotic activity for the benign LM designation. SMTs of female genital tract can be assessed with criteria similar to uterine tumours. Because of the rarity of these tumours, experience is more limited, and more caution is needed to assess the potential of tumours with mitotic activity and atypia. This review summarizes the current knowledge, guidelines, prognostic data and controversies for the classification of SMTs of soft tissue and most visceral sites.
authors.affiliation: Department of Soft Tissue Pathology, Armed Forces Institute of Pathology, 6825 16th Street NW, Bldg. 54, Rm. G090, Washington, DC 20306-6000, USA. miettinen@afip.osd.mil
authors.forename: M
authors.initials: M
authors.lastname: Miettinen
authors.forename: J F
authors.initials: JF
authors.lastname: Fetsch
mesh_terms: D000199:Actins / Q000032:analysis; D003937:Diagnosis, Differential; D006801:Humans; D007150:Immunohistochemistry; D007889:Leiomyoma / Q000378:metabolism / Q000473:pathology; D007890:Leiomyosarcoma / Q000378:metabolism / Q000473:pathology; D008940:Mitotic Index; D009130:Muscle, Smooth / Q000737:chemistry / Q000473:pathology*; D009379:Neoplasms, Muscle Tissue / Q000145:classification / Q000378:metabolism / Q000473:pathology*; D011379:Prognosis
chemical_list: D000199:Actins